TransMedics Group, Inc.
TMDX
$133.81
-$8.12-5.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.20% | 48.09% | 64.43% | 82.74% | 109.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.20% | 48.09% | 64.43% | 82.74% | 109.09% |
| Cost of Revenue | 37.92% | 51.56% | 77.26% | 105.03% | 151.11% |
| Gross Profit | 43.45% | 45.85% | 56.70% | 70.08% | 87.58% |
| SG&A Expenses | 17.09% | 24.60% | 36.78% | 43.44% | 44.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.95% | 37.65% | 54.55% | 67.56% | 81.35% |
| Operating Income | 186.82% | 169.55% | 250.24% | 7,631.13% | 407.01% |
| Income Before Tax | 184.43% | 4,906.22% | 529.61% | 234.15% | 187.70% |
| Income Tax Expenses | 6,856.25% | 259.87% | 176.41% | 119.23% | 101.10% |
| Earnings from Continuing Operations | 181.16% | 2,288.73% | 580.13% | 241.70% | 191.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 181.16% | 2,288.73% | 580.13% | 241.70% | 191.22% |
| EBIT | 186.82% | 169.55% | 250.24% | 7,631.13% | 407.01% |
| EBITDA | 135.74% | 134.31% | 183.01% | 560.98% | 1,114.64% |
| EPS Basic | 173.50% | 2,410.18% | 564.23% | 239.32% | 189.85% |
| Normalized Basic EPS | 160.64% | 134.92% | 178.26% | 1,306.25% | 437.77% |
| EPS Diluted | 165.89% | 5,763.75% | 494.65% | 230.87% | 184.64% |
| Normalized Diluted EPS | 134.23% | 112.95% | 162.11% | 1,385.08% | 418.71% |
| Average Basic Shares Outstanding | 2.56% | 2.69% | 2.54% | 2.19% | 1.96% |
| Average Diluted Shares Outstanding | 11.87% | 10.68% | 9.01% | 7.04% | 8.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |